[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354392-105":59,"doc-detail-354392-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","unmasking-the-common-enemy-drug-resistance-mechanisms-across-three-different-egfr-inhibitor-generations-are-associated-with-co-targetable-alterations-in-extracellular-matrix-signaling","Unmasking the common enemy - drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling","","Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) markedly improve non-small cell lung cancer outcomes, yet acquired resistance limits durable benefit. Shared resistance mechanisms across first-, second-, and third-generation EGFR inhibitors are unclear. Drug-resistant HCC827 and NCI-H1975 models spanning three generations were generated via stepwise gefitinib, dacomitinib, and osimertinib selection and analyzed by proteomics, pathway inference, and validation using western blotting and droplet digital PCR, combined with functional assays to map cross-resistance and reversibility.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unmasking-the-common-enemy-drug-resistance-mechanisms-across-three-different-egfr-inhibitor-generations-are-associated-with-co-targetable-alterations-in-extracellular-matrix-signaling/354392/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unmasking-the-common-enemy-drug-resistance-mechanisms-across-three-different-egfr-inhibitor-generations-are-associated-with-co-targetable-alterations-in-extracellular-matrix-signaling/354392.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address?","Question",{"text":113,"@type":114},"EGFR-TKI treatment improves non-small cell lung cancer, but acquired resistance eventually undermines long-term efficacy. The study focuses on identifying mechanisms that may be shared across different generations of EGFR inhibitors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were drug-resistant cell models generated and compared?",{"text":118,"@type":114},"HCC827 and NCI-H1975 cells were stepwise selected over 10 months using gefitinib, dacomitinib, and osimertinib to represent first-, second-, and third-generation EGFR-TKIs. Resistant and parental lines were compared using global proteomics and bioinformatic pathway analyses, then validated with western blotting and droplet digital PCR.",{"name":120,"@type":111,"acceptedAnswer":121},"What resistance mechanisms and targetable pathways were highlighted?",{"text":122,"@type":114},"Alterations in extracellular matrix components and signaling proteins, including FN1, FAK, and YAP1, were validated as synergistically targetable drivers across all three drug generations. Shared dysregulations in cancer stemness regulators (Hedgehog, Notch) and anti-apoptotic and drug-efflux factors (BCL-2, ABCG2) were also reported, and transcriptomics linked FN1 and collagen-related genes to relapse and poor survival.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354392,1790818505,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":26,"preview_page_count":19,"preview_urls":146},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Zhang et al. Cell Communication and Signaling (2026) 24:376  \n[https://doi.org/10.1186/s12964-026-02927-8](https://doi.org/10.1186/s12964-026-02927-8)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nUnmasking the common enemy: drug  resistance mechanisms across three different EGFR inhibitor generations are associated  \nwith co-targetable alterations in extracellular matrix signaling  \nYu Zhang1†, Okan Gültekin2,3†, Rudolf Kupčík4, Youssif Budagaga1, Dimitrios Vagiannis1, Ziba Sabet1, Kaisa Lehti2,5 and Jakub Hofman1*  \nAbstract  \nBackground Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have transformed non-small cell lung cancer (NSCLC) treatment, offering substantial survival benefits. However, acquired resistance remains a significant obstacle, undermining long-term efficacy. While specific mechanisms of EGFR-TKI resistance have been reported, potential shared mechanisms across EGFR-TKI generations have remained unclear.  \nMethods Drug-resistant HCC827 and NCI-H1975 cells were developed by a 10-month stepwise selection using gefitinib, dacomitinib, and osimertinib, representing first, second, and third EGFR-TKI generations, respectively. Global proteomes ofthe resistant and parental NSCLC cell lines were compared using liquid chromatography tandem mass spectrometry. After bioinformatic pathway analyses, the candidate protein and gene alterations were validated by western blotting and droplet digital PCR. Drug (cross-)resistance patterns and reversal responses were quantified by MTT assay after single and combination drug treatments, or gene silencing by small interfering RNA. Invasive cell activities were evaluated in spheroid models within three-dimensional (3D) collagen matrices. Bioinformatics analyses of open-access transcriptomic datasets were applied to explore gene expression alterations linked to clinical EGFR mutations and disease prognosis and relapse.  \nResults We established EGFR-TKI-resistant NSCLC cell lines for all three drug generations, demonstrating crossresistance and significantly enhanced invasive potential in 3D collagen. Notably, extracellular matrix components and signaling proteins (FN1, FAK, YAP1) were found altered and validated as synergistically targetable resistance drivers across all three drug generations, irrespective of cellular background. Moreover, the second-and third-generation models shared co-targetable dysregulations in cancer stemness regulators (Hedgehog, Notch), anti-apoptotic protein  \n†Yu Zhang and Okan Gültekin contributed equally to this work.  \n*Correspondence: Jakub Hofman [hofmanj@faf.cuni.cz](hofmanj@faf.cuni.cz)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nZhang et al. Cell Communication and Signaling (2026) 24:376 Page 2 of 24  \nBCL-2, and the drug efflux transporter ABCG2 . Finally, transcriptomic analysis showed that in human EGFR-positive NSCLC tumors, overexpression of FN1 and collagen-related genes was associated with post-treatment relapse and po","cbCaisq2FI7263oJ","https://ap.wps.com/l/cbCaisq2FI7263oJ","pdf",8184968,24,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Plain English summary\n## Keywords\n# Background","[{\"question\":\"What problem does the study address?\",\"answer\":\"EGFR-TKI treatment improves non-small cell lung cancer, but acquired resistance eventually undermines long-term efficacy. The study focuses on identifying mechanisms that may be shared across different generations of EGFR inhibitors.\"},{\"question\":\"How were drug-resistant cell models generated and compared?\",\"answer\":\"HCC827 and NCI-H1975 cells were stepwise selected over 10 months using gefitinib, dacomitinib, and osimertinib to represent first-, second-, and third-generation EGFR-TKIs. Resistant and parental lines were compared using global proteomics and bioinformatic pathway analyses, then validated with western blotting and droplet digital PCR.\"},{\"question\":\"What resistance mechanisms and targetable pathways were highlighted?\",\"answer\":\"Alterations in extracellular matrix components and signaling proteins, including FN1, FAK, and YAP1, were validated as synergistically targetable drivers across all three drug generations. Shared dysregulations in cancer stemness regulators (Hedgehog, Notch) and anti-apoptotic and drug-efflux factors (BCL-2, ABCG2) were also reported, and transcriptomics linked FN1 and collagen-related genes to relapse and poor survival.\"}]","Unmasking the common enemy - drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling | PDF",1790110427,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c124f8ddc0b1e60b1abb4466816bb09.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/364149b78c235bda2212cff8757c6fd2.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/428d36b48e449c79645296c89db21372.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6636c045b876c8eaabdc6745784e0865.webp",980,1306]